A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

Also called NCT05318326

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
Chengdu Easton Biopharmaceuticals Co,Ltd (from the registry)
Registry
  • NCT NCT05318326
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05318326. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
Intervention (Drug)
placebo group
Intervention (Drug)
Yogliptin 400mg group
Intervention (Drug)
Yogliptin 200mg group
Lead sponsor
Chengdu Easton Biopharmaceuticals Co,Ltd (class: industry)

Record details

Record id
cardio:ct-nct05318326
Content hash
b766faeb110939c3519f828f53e8d2400fd55860191a3b23a898458b6d5da028